TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Hits Expectations

TriSalus Life Sciences (NASDAQ:TLSI) announced its earnings results on Thursday. The company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35), Zacks reports. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Trading Down 1.3 %

TLSI stock traded down $0.07 during midday trading on Thursday, hitting $5.51. The company’s stock had a trading volume of 18,140 shares, compared to its average volume of 42,757. The firm’s 50-day moving average is $5.38 and its 200-day moving average is $4.73. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42. The company has a market cap of $168.02 million, a PE ratio of -2.21 and a beta of 0.48.

Insider Transactions at TriSalus Life Sciences

In related news, CFO James Emmett Young acquired 6,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were bought at an average price of $5.65 per share, for a total transaction of $33,900.00. Following the completion of the transaction, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $169,500. This trade represents a 25.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mary T. Szela bought 4,826 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was bought at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the acquisition, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at $2,327,906.26. The trade was a 1.14 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 54,856 shares of company stock worth $294,608 over the last quarter. 32.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TLSI has been the topic of several research reports. Lake Street Capital began coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 price objective on the stock. Roth Mkm restated a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Finally, Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $11.56.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.